Filtered By:
Cancer: Ovarian Cancer
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 759 results found since Jan 2013.
Downregulation of Methyltransferase-Like 14 Promotes Ovarian Cancer Cell Proliferation Through Stabilizing TROAP mRNA
In conclusion, METTL14 overexpression decreased ovarian cancer proliferation by inhibition of TROAP expression via an m6A RNA methylation-dependent mechanism.
Source: Frontiers in Oncology - February 18, 2022 Category: Cancer & Oncology Source Type: research
Long Noncoding RNA RMRP Contributes to Paclitaxel Sensitivity of Ovarian Cancer by Regulating miR-580-3p/MICU1 Signaling
J Oncol. 2022 Jan 29;2022:8301941. doi: 10.1155/2022/8301941. eCollection 2022.ABSTRACTOvarian cancer is a prevalent female malignancy affecting the health and life of an increasing population of women around the world. Paclitaxel (PTX) resistance is a significant clinical problem in the treatment of ovarian cancer. However, the regulation mechanism of PTX resistance remains unclear. In this investigation, we reported an innovative function of the long noncoding RNA RMRP in promoting PTX resistance and glycolysis of ovarian cancer cells. We observed that RMRP was highly expressed in the ovarian cancer samples, in which the...
Source: Journal of Oncology - February 8, 2022 Category: Cancer & Oncology Authors: Lingling Li Saitian Zeng Liang Guo Ping Huang Jie Xi Jing Feng Qian Li Yanying Li Xiyun Xiao Ruixue Yan Jiyan Zhang Source Type: research
Corrigendum The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma
Int J Oncol. 2022 Mar;60(3):28. doi: 10.3892/ijo.2022.5318. Epub 2022 Feb 4.ABSTRACTSubsequently to the publication of the above article [and an already published Corrigendum that has indicated a corrected version of Fig. 6 (DOI: 10.3892/ijo.2020.5131; published online on October 12, 2020)], the authors have realized that some incorrect data were also included in Fig. 3 in their paper; essentially, Fig. 3A, which was intending to show the siRNA knockdown data for NFATc1 expression in xenograft tumor tissue via immunohistochemical staining, was inadvertently derived from the same data as that shown for Fig. 4F. The correcte...
Source: International Journal of Oncology - February 4, 2022 Category: Cancer & Oncology Authors: Long Li Jihui Yu Zhaoning Duan Hong-Xing Dang Source Type: research
The inhibitory role of si-UBB delivered by degradable dendrimers-based lipid nanoparticles in ovarian cancer
Conclusions5A2SC8 complex was a safe and efficient gene delivery vehicle and ubiquitin B was a potential target for the ovarian cancer targeted therapy.
Source: Cancer Nanotechnology - January 29, 2022 Category: Cancer & Oncology Source Type: research
Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation, invasion and migration of A2780 and SKOV3 cells
Conclusion: Patients with high METTL14 expression have a worse prognosis in ovarian cancer, which may increase the m6A modification of ovarian cancer cells and promote cells proliferation, invasion and migration.PMID:35090245 | DOI:10.3760/cma.j.cn112141-20210925-00553
Source: Cancer Control - January 28, 2022 Category: Cancer & Oncology Authors: Y S Wei D S Yao L Li Y Lu X M Yang W G Zhang Source Type: research
PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF- κB Signaling Pathway in Ovarian Cancer
Glycolysis has been reported to be critical for cancer stem cells (CSCs), which are associated with tumor chemoresistance, metastasis and recurrence. Thus, selectively targeting glycolytic enzymes may be a potential therapy for ovarian cancer. 6‐phosphofructo‐2‐kinase/fructose‐2,6‐biphosphatase 3 (PFKFB3), the main source of fructose-2,6-bisphosphate, controls the first committed step in glycolysis. We investigate the clinical significance and roles of PFKFB3 in ovarian cancer using in vitro and in vivo experiments. We demonstrate that PFKFB3 is widely overexpressed in ovarian cancer and correlates with advanced ...
Source: Frontiers in Oncology - January 28, 2022 Category: Cancer & Oncology Source Type: research
CD105 expression is associated with invasive capacity in ovarian cancer and promotes invasiveness by inhibiting NDRG1 and regulating the epithelial-mesenchymal transition
This study investigates the association of CD105 (endoglin) with the invasiveness of paclitaxel-resistant ovarian cancer (OC) cells and explores the potential mechanism. A paclitaxel-resistant OC cell line OC3/TAX300, which expresses the stem cell marker CD105 and has a high invasive potential, was established in our previous study. After CD105 knockdown using CD105 siRNA, the invasiveness of the OC cells was decreased, and the chemo-resistance was reversed, but the CD105 overexpression was related to the poor survival of the primary OC patients. The differentially expressed genes were investigated in the OC cells after th...
Source: Cell Research - December 27, 2021 Category: Cytology Authors: Jin Zhang Xiubo Sang Rui Zhang Jingjing Chi Wenpei Bai Source Type: research
Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature
Nanomedicine, Ahead of Print.
Source: Future Medicine: Nanomedicine - December 21, 2021 Category: Nanotechnology Authors: Abdus Subhan Sara Aly Attia Vladimir P Torchilin Source Type: research
GSE142567 RNA sequencing (RNA-SEQ) of FOXM1 knockdown by siRNA in ovarian cancer cells
Conclusions: These data reveal FOXM1 as a driver oncogenic transcription factor that promotes ovarian cancer malignancy which might be a potential drug target in HGSOC.
Source: GEO: Gene Expression Omnibus - December 1, 2021 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
